CLEE011A2301 Study of a new drug for hormone receptor positive breast
Research type
Research Study
Full title
A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who received no prior therapy for advanced disease
IRAS ID
146264
Contact name
David Cameron
Contact email
Sponsor organisation
Novartis Pharmaceuticals UK Limited
Eudract number
2013-003084-61
Clinicaltrials.gov Identifier
REC name
West of Scotland REC 1
REC reference
14/WS/0109
Date of REC Opinion
21 May 2014
REC opinion
Further Information Favourable Opinion